X

Trial Profile

A Multicenter, Open Label Study Assessing the Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fremanezumab (Primary)
Indications Migraine
Focus Therapeutic Use

Most Recent Events

12 Jun 2022 Primary endpoint (Change in Migraine Interictal Burden Scale (MIBS-4) Scores From Baseline to Weeks 4, 8, and 12.) has been met as per results presented at the 64th Annual Scientific Meeting of the American Headache Society
12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society
08 Mar 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com